Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Biotinylated PAMAM Dendrimers-mediated Delivery of Temozolomide for the Effective Management of Glioblastoma

Sanya Batheja – Research Scholar, Department of Pharmacy, Central University of Rajasthan; Rakesh Kumar Sahoo – Research Scholar, Department of Pharmacy, Central University of Rajasthan; Parag Jain – Associate Professor, Rungta College of Pharmaceutical Sciences and Research; Ajazuddin . – Director, Rungta College of Pharmaceutical Sciences and Research; Umesh Gupta – Associate Professor, Department of Pharmacy, Central University of Rajasthan
Introduction:

Glioblastoma (GBM) accounts for nearly half of all gliomas and remains associated with poor prognosis due to limited brain penetration and systemic toxicity of temozolomide (TMZ). Targeted nanocarrier systems offer a promising strategy to overcome these limitations. This study aimed to develop biotinylated PAMAM (G3.0, NH2) dendrimers conjugated and encapsulated with TMZ to enhance cellular uptake, controlled drug release, and brain biodistribution for improved GBM therapy. This might potentially lower the high dosage needs and related adverse effects of traditional TMZ therapy.

Learning Objectives:

  • Upon completion, participant will be able to demonstrate how biotin affects dendrimers uptake and TMZ IC50 levels.
  • Upon completion, participant will be able to compare drug release and stability of dendrimeric formulations.
  • Upon completion, participant will be able to appraise how targeted dendrimer improve brain biodistribution of drug.